Site-Cost Line Item Charges on the Rise
Applied Clinical Trials
Tufts CSDD
Clinical grants are growing increasingly sophisticated. Consquently, investigator site startup costs have become increasingly complex as well. Clinical sites are charging for a greater amount of site-cost line items. In addition, sites are charging more for those line items.
TTC's GrantPlan database contains grants from 76% of global clinical trials. GrantPlan tracks all the site-cost line items from clinical grants. The most common site costs are general site startup administrative fees, advertising, IRB fees, and pharmacy fees.
In 2010 the average number of line items included in global clinical grant site costs was 2.9 line items. That number increased to 3.0 in 2011, and is currently approaching 3.1 line items in 2012. Advertising fees are most responsible for the additional line items.
Additionally, sites are charging more for individual line items. The single most common site cost is the general administrative site startup fee. Between 2010 and 2011 the average site startup administrative fee increased 8%. Halfway through 2012, the average startup administrative fee has increased 3%.
—TTC (for more information, please contact help@ttc-llc.com)
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
